在接种COVID-19疫苗后出现新发作的风险:一项自我控制的病例系列研究
Hwa Yeon Ko1, Dongwon Yoon1,2, Ju Hwan Kim1,2
1Sungkyunkwan University, School of Pharmacy, Suwon, Gyeong gi-do, Korea.
Epidemiology and health
|May 9, 2025
概括
接种COVID-19疫苗不会增加新发作 (NOS) 的风险. 这项研究为临床决策和公众对COVID-19疫苗的信心提供了安全证据.
科学领域:
- 神经学 神经学
- 疫苗学 疫苗学 疫苗学
- 公共卫生 公共卫生
背景情况:
- 在COVID-19疫苗接种后出现新发作 (NOS) 的报道存在,但安全性数据有限.
- 调查COVID-19疫苗接种和NOS之间的关联对于疫苗安全性评估至关重要.
研究的目的:
- 为了评估COVID-19疫苗接种后新发作 (NOS) 的风险.
- 为COVID-19疫苗提供强有力的安全证据.
主要方法:
- 一个使用全国数据库的自控案例系列研究 (2021年2月至2022年10月).
- 包括接受了BNT162b2,ChAdOx1 nCoV-19,mRNA-1273,NVX-CoV2373或Ad26.COV2.S疫苗的成年人 (≥18岁).
- 在接种疫苗后的28天窗口中的NOS风险与剩余的观察期相比.
主要成果:
- 在接种疫苗后28天内没有发现NOS的风险增加 (IRR,0.99;95% CI,0.94-1.05).
- 亚组分析显示大多数疫苗没有显著增加.
- 对于mRNA-1273 (IRR,1.21;95% CI,1.04-1.42) 观察到略有增加的风险.
结论:
- 接种COVID-19疫苗与新发作发作的风险增加无关.
- 这些发现支持COVID-19疫苗的安全性,并有助于临床决策.
- 这些证据可以增强公众对COVID-19疫苗接种计划的信任.
相关概念视频
Seizures: Classification
284
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
284
Antiepileptic Drugs: GABAergic Pathway Potentiators
260
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
260
Antiepileptic Drugs: Glutamate Antagonists
249
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
249
Antiepileptic Drugs: Sodium Channel Blockers
262
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
262
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
187
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
187
Antiepileptic Drugs: Potassium Channel Activators
126
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
126


